Chemical Properties of 'Lifitegrast D4' |
|
CAT No. : |
CS-P-08463 |
CAS Registry No. : | 1025967-78-5 (Unlabeled) |
Category : | Isotope Labelled Compounds |
Molecular Weight: | 619.50 g/mol |
Molecular Formula : | C29H20D4Cl2N2O7S |
OTHER INFORMATION of 'Lifitegrast D4' |
|
IUPAC Name : | (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid |
Solubility : | Soluble |
Use Classification : | Human Drugs -> EU pediatric investigation plans |
Hazard Class : | Repr. 2 (100%) |
EC Number : | 813-044-8 |
UNII : | 038E5L962W |
RXCUI : | 1801820 |
MeSH Entry Terms : | (2S)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid |
Other Synonyms : | Lifitegrast |
Removed Synonyms : | D04ISS |
Label Ingredient : | LIFITEGRAST |
NDC Code : | 0078-0911-05, 0078-0911-12, 0078-0911-94, 0078-0911-95, 54092-606-01, 54092-606-02, 54092-606-04, 54092-606-06, 54092-606-07 |
Toxicity Summary : | Some adverse effects in 5-25% of the patients include instillation site irritation, dysgeusia and reduced visual acuity. There is no evidence or reports of potential carcinogenic, mutagenic or fertility-altering effects of this drug. |
Protein Binding : | Human plasma protein binding of lifitegrast was approximately 99%, independent of concentration (50 to 1000ng/mL). Binding to isolated human serum albumin was 95% to 98%, and 31.6% to 51.1% to human α1-acid glycoprotein. |
Exact Mass : | 614.0681277 |
InChI : | InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1 |
InchIKey : | JFOZKMSJYSPYLN-QHCPKHFHSA-N |
Canonical SMILES : | CS(=O)(=O)C1=CC=CC(=C1)CC(C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl |
Isomeric SMILES : | CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl |
Product Description : | Lifitegrast is an N-acyl-L-alpha-amino acid obtained by formal condensation of the carboxy group of N-[2-(1-benzofuran-6-carbonyl)]-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid with the amino group of 3-(methanesulfonyl)-L-phenylalanine. Used for treatment of keratoconjunctivitis sicca (dry eye syndrome). It has a role as an anti-inflammatory drug and a lymphocyte function-associated antigen-1 antagonist. It is a L-phenylalanine derivative, a sulfone, a N-acyl-L-alpha-amino acid, a member of isoquinolines and a member of 1-benzofurans. |
Custom Duty : | Applicable |
Port of Loading : | Canada |
Expected Dispatch : | 2-3 Weeks |
Taxes : | Not Applicable |
Refund Policy : | 30-days money back |
Custom Duty : | Applicable |
Port of Loading : | Canada |
Expected Dispatch : | 2-3 Weeks |
Taxes : | Not Applicable |
Refund Policy : | 30-days money back |
Looking for a discounted price or need more info for 'Lifitegrast D4 (CS-P-08463)' ?
If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.